Testosterone and luteinizing hormone predict semen parameter improvement in infertile men treated with anastrozole.

Humans Male Anastrozole / therapeutic use Follicle Stimulating Hormone Infertility, Male / diagnosis Luteinizing Hormone Retrospective Studies Semen Testosterone
Anastrozole aromatase inhibitor gonadotropins male infertility semen analysis

Journal

Fertility and sterility
ISSN: 1556-5653
Titre abrégé: Fertil Steril
Pays: United States
ID NLM: 0372772

Informations de publication

Date de publication:
10 2023
Historique:
received: 15 02 2023
revised: 22 06 2023
accepted: 26 06 2023
medline: 23 10 2023
pubmed: 2 7 2023
entrez: 1 7 2023
Statut: ppublish

Résumé

To identify patient factors associated with a clinically significant improvement in semen parameters among infertile men treated with the aromatase inhibitor anastrozole. Multi-institutional retrospective cohort study. Two Tertiary Academic Medical Centers. A total of 90 infertile men treated at 2 tertiary academic medical centers who met inclusion criteria and obtained pretreatment and posttreatment semen analyses. Prescription of anastrozole (median 3 mg/wk). Upgrade in the World Health Organization sperm concentration category (WHO-SCC). Univariate logistic regression, multivariable logistic regression, and partitioning analyses were performed to identify statistically significant patient factors capable of predicting treatment response. With anastrozole treatment, 46% (n = 41/90) of men responded favorably with a WHO-SCC upgrade, and 12% (n = 11/90) experienced a downgrade. Responders exhibited lower pretreatment levels of luteinizing hormone (LH, 4.7 vs. 8.3 IU/L) and follicle-stimulating hormone (4.7 vs. 6.7 IU/mL), higher pretreatment levels of testosterone (T, 356 vs. 265 ng/dL), and similar baseline level of estradiol (E Anastrozole therapy decreases serum E

Identifiants

DOI: 10.1016/j.fertnstert.2023.06.032 PMID: 37392782
pubmed: 37392782
pii: S0015-0282(23)00635-0
doi: 10.1016/j.fertnstert.2023.06.032
pii:
doi:

Substances chimiques

Anastrozole 2Z07MYW1AZ
Follicle Stimulating Hormone 9002-68-0
Luteinizing Hormone 9002-67-9
Testosterone 3XMK78S47O

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

746-754

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests B.D.N. has nothing to disclose. T.J. has nothing to disclose. C.M.L. has nothing to disclose. T.S. has nothing to disclose. N.M. has nothing to disclose. R.C. has nothing to disclose. J.M. is a consultant and speaker for Halozyme Therapeutics, Boston Scientific, and Endo Pharmaceuticals. N. P. is a speaker for Halozyme Therapeutics. A.S.N. has nothing to disclose. S.C.V. has nothing to disclose. S.V.E. has nothing to disclose. S.D.L. has nothing to disclose.

Auteurs

Bryan D Naelitz (BD)

Glickman Urological and Kidney Institute, Cleveland Clinic Foundation, Cleveland, Ohio. Electronic address: naelitb2@ccf.org.

Tommy Jiang (T)

David Geffen School of Medicine at University of California-Los Angeles, Los Angeles, California.

Carlos Munoz-Lopez (C)

Cleveland Clinic Lerner College of Medicine of Case Western Reserve University School of Medicine, Cleveland, Ohio.

John Tucker Sigalos (JT)

Department of Urology, University of California, Los Angeles, Los Angeles, California.

Neilufar Modiri (N)

David Geffen School of Medicine at University of California-Los Angeles, Los Angeles, California.

Rosella Cannarella (R)

Glickman Urological and Kidney Institute, Cleveland Clinic Foundation, Cleveland, Ohio.

Jesse N Mills (JN)

Department of Urology, University of California, Los Angeles, Los Angeles, California.

Neel Parekh (N)

Glickman Urological and Kidney Institute, Cleveland Clinic Foundation, Cleveland, Ohio.

Amy S Nowacki (AS)

Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio.

Sarah C Vij (SC)

Glickman Urological and Kidney Institute, Cleveland Clinic Foundation, Cleveland, Ohio.

Sriram V Eleswarapu (SV)

Department of Urology, University of California, Los Angeles, Los Angeles, California.

Scott D Lundy (SD)

Glickman Urological and Kidney Institute, Cleveland Clinic Foundation, Cleveland, Ohio.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Testosterone and luteinizing hormone predict...
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Azoles › Triazoles › Anastrozole › Testosterone and luteinizing hormone predict...
questionsmedicales.fr › Acides aminés, peptides et protéines › Peptides › Hormones peptidiques › Hormones hypophysaires › Hormones antéhypophysaires › Gonadotrophines hypophysaires › Hormone folliculostimulante › Testosterone and luteinizing hormone predict...
questionsmedicales.fr › Maladies urogénitales › Maladies urogénitales de l'homme › Maladies de l'appareil génital mâle › Infertilité masculine › Testosterone and luteinizing hormone predict...
questionsmedicales.fr › Acides aminés, peptides et protéines › Peptides › Hormones peptidiques › Hormones hypophysaires › Hormones antéhypophysaires › Gonadotrophines hypophysaires › Hormone lutéinisante › Testosterone and luteinizing hormone predict...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études rétrospectives › Testosterone and luteinizing hormone predict...
questionsmedicales.fr › Liquides et sécrétions biologiques › Sécrétions corporelles › Sperme › Testosterone and luteinizing hormone predict...
questionsmedicales.fr › Hormones gonadiques › Hormones sexuelles stéroïdiennes › Congénères de la testostérone › Testostérone › Testosterone and luteinizing hormone predict...